ANAB earnings: real EPS beat/miss history, analyst consensus Buy, P/E -61.89. Updated 2026-07-23.
AnaptysBio (ANAB) Research Hub
AnaptysBio (ANAB) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 53.87 USD (-3.29%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -61.89, market cap 2.26B. This hub links to the full technical, earnings and options research available for ANAB.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 53.87 USD (-3.29%) |
| 52-week range | 50.24 USD – 70.41 USD |
| Trend regime | Range |
| 14-day RSI | 42.5 (Bearish) |
| Trailing P/E | -61.89 |
| Market cap | 2.26B |
| Dividend yield | 0.00% |
Available research for ANAB
Covered Call on ANAB: how it works, illustrative setup around the real 53.87 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on ANAB: how it works, illustrative setup around the real 53.87 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on ANAB: how it works, illustrative setup around the real 53.87 USD price, max profit/loss, breakeven and when to use it. Educational.
ANAB technical analysis: range, last 53.87 USD, RSI 42.5, 52w range 50.24 USD–70.41 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is ANAB in?
AnaptysBio (ANAB) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is ANAB in an uptrend or downtrend?
As of 2026-09-11, ANAB is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is ANAB's trailing P/E ratio?
ANAB's trailing P/E is -61.89, with a market cap of 2.26B. See the earnings research page for full valuation detail.